ProCE Banner Activity

CME

A Conversation With the Myeloma Experts: Making Sense of the Evolving Treatment Landscape

Multimedia

Watch this on-demand webcast from an ASH satellite symposium on applying recent clinical findings in myeloma, including considerations for smoldering myeloma, treatment decisions for newly diagnosed patients, and the latest data on therapy for relapsed/refractory disease.

Physicians: Maximum of 2.50 AMA PRA Category 1 Credits

Released: January 24, 2023

Expiration: January 23, 2024

No longer available for credit.

Share

Faculty

Brian G. M. Durie

Brian G. M. Durie, MD

National Director, Hematologic Malignancies and Multiple Myeloma
Aptium Oncology, Inc.
Co-Chair, Myeloma Committee – SWOG
Chairman, International Myeloma Foundation
Specialist, Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Yi Lin

Yi Lin

Professor of Medicine, Division of Hematology
Division of Experimental Pathology
Chair, Cell Therapy Cross-Disciplinary Group
Mayo Clinic Comprehensive Cancer Center
Associate Medical Director, Mayo Clinic Center for Regenerative Biotherapeutics
Mayo Clinic
Rochester, Minnesota

Thomas G. Martin

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Philippe Moreau

Philippe Moreau, MD

Professor of Clinical Hematology
University Hospital of Nantes
Nantes, France

S. Vincent Rajkumar

S. Vincent Rajkumar, MD

Edward W. and Betty Knight Scripps–Edward C. Rosenow, III, MD
Professor of Medicine
Associate Editor, Mayo Clinic Proceedings
Mayo Clinic
Rochester, Minnesota

Jesús F. San-Miguel

Jesús F. San-Miguel, MD, PhD

Head, Hematology Department
Professor of Medicine
Hospital Universitario de Salamanca and Centro de Investigación del Cáncer
University of Salamanca
Salamanca, Spain

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Janssen administered by Scientific Affairs

Karyopharm Therapeutics Inc.

Pfizer, Inc.

Regeneron Pharmaceuticals, Inc.

Takeda Pharm USA

Partners

International Myeloma Foundation

ProCE Banner

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with multiple myeloma.

Program Learning Goal

The goal of this activity is to improve learners’ knowledge of and competence in applying practice-changing clinical data and expert recommendations to optimize the care of their patients with multiple myeloma.

Learning Objectives

  • Initiate timely systemic treatment for appropriate patients based on the latest multiple myeloma diagnostic criteria, staging criteria, and risk factors
  • Develop individualized treatment strategies for patients with newly diagnosed multiple myeloma through consideration of the available clinical data, as well as risk assessment, comorbidities, and patient age/fitness and preferences
  • Appraise the efficacy and safety evidence of novel combination therapeutic regimens for patients with multiple myeloma
  • Select optimal therapies for patients with heavily pretreated relapsed/refractory multiple myeloma based on individual patient and disease characteristics, as well as response to and tolerance of previous therapies
  • Identify patients with relapsed/refractory multiple myeloma who would be eligible for enrollment on key ongoing clinical trials
  • Recognize adverse events associated with new or novel multiple myeloma treatments

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Brian G. M. Durie, MD

National Director, Hematologic Malignancies and Multiple Myeloma
Aptium Oncology, Inc.
Co-Chair, Myeloma Committee – SWOG
Chairman, International Myeloma Foundation
Specialist, Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Brian G.M. Durie, MD, has no relevant financial relationships to disclose.

Faculty Disclosure

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD: consultant/advisor (paid to institution): AbbVie, Amgen, Antengene, ArcellX, AstraZeneca, BeiGene, Bluebird Bio, Bristol-Myers Squibb, Janssen, K36, Loxo Oncology, Oncopeptides, Roche/Genentech, Sanofi; consultant/advisor: Secura Biotherapeutics, Takeda, Trillium; researcher (paid to institution): AbbVie, Allogene, Amgen, AstraZeneca, Bristol-Myers Squibb, Carsgen, GlaxoSmithKline, Janssen, Novartis, Roche/Genentech, Regeneron, Takeda.

Yi Lin,

Professor of Medicine, Division of Hematology
Division of Experimental Pathology
Chair, Cell Therapy Cross-Disciplinary Group
Mayo Clinic Comprehensive Cancer Center
Associate Medical Director, Mayo Clinic Center for Regenerative Biotherapeutics
Mayo Clinic
Rochester, Minnesota

Yi Lin, MD, PhD: consultant (paid to institution): A2 Biotherapeutics, Fosun, Gamida Cells, Iovance, Kite, Legend Biotech, NekTar Therapeutics, NexImmune, Novartis, Sorrento; data and safety monitoring board member: Pfizer; scientific advisory committee member: NexImmune, Chimeric Biotherapeutics; researcher (paid to institution): Bristol-Myers Squibb, BlueBird Bio, Boston Scientific, Kite/Gilead, Merck, Takeda.

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Thomas G. Martin, MD: consultant: GlaxoSmithKline, Legend Biotech; researcher (paid to institution): Amgen, Janssen, Sanofi.

Philippe Moreau, MD

Professor of Clinical Hematology
University Hospital of Nantes
Nantes, France

Philippe Moreau, MD: consultant/advisor/speaker: AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen, Sanofi, Takeda.

S. Vincent Rajkumar, MD

Edward W. and Betty Knight Scripps–Edward C. Rosenow, III, MD
Professor of Medicine
Associate Editor, Mayo Clinic Proceedings
Mayo Clinic
Rochester, Minnesota

S. Vincent Rajkumar, MD, has no relevant financial relationships to disclose.

Jesús F. San-Miguel, MD, PhD

Head, Hematology Department
Professor of Medicine
Hospital Universitario de Salamanca and Centro de Investigación del Cáncer
University of Salamanca
Salamanca, Spain

Jesús F. San-Miguel, MD, PhD: consultant/advisor/speaker: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Haemalogix, Janssen, Karyopharm, Merck Sharpe and Dohme, Novartis, Takeda, Regeneron, Roche, Sanofi, SecuraBio.

The planners and content peer reviewers from Clinical Care Options, LLC and the International Myeloma Foundation (IMF) do not have any relevant financial relationships to disclose.

Jim Mortimer: individual publicly traded stocks and stock options: AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 2.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 24, 2023, through January 23, 2024:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.